Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Gil

Showing results (191-200 of 229) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|July 2, 2019
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Carla M L van Herpen, Cristina Saura, et al.
Plos One|January 10, 2013
Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosisFélix Claverie-Martín, Víctor García-Nieto, Cesar Loris, et al.
International Journal of Molecular Sciences|July 29, 2023
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking SurgeryAndrea Plaja, Iris Teruel, Maria Ochoa-de-Olza, et al.
Cancers|September 23, 2022
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse SettingMargarita Romeo, Marta Gil-Martín, Lydia Gaba, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2014
Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adultsGema Ariceta, Enrique Lara, Juan A Camacho, et al.
Gynecologic Oncology|September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerDanny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Pageof 23

Showing results (191-200 of 229) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|July 2, 2019
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Carla M L van Herpen, Cristina Saura, et al.
Plos One|January 10, 2013
Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosisFélix Claverie-Martín, Víctor García-Nieto, Cesar Loris, et al.
International Journal of Molecular Sciences|July 29, 2023
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking SurgeryAndrea Plaja, Iris Teruel, Maria Ochoa-de-Olza, et al.
Cancers|September 23, 2022
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse SettingMargarita Romeo, Marta Gil-Martín, Lydia Gaba, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2014
Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adultsGema Ariceta, Enrique Lara, Juan A Camacho, et al.
Gynecologic Oncology|September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerDanny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Pageof 23